ACRV – acrivon therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors [Yahoo! Finance]
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why [Yahoo! Finance]
Acrivon Therapeutics (ACRV) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Form S-8 Acrivon Therapeutics,
Form 8-K Acrivon Therapeutics, For: Mar 19
Form 10-K Acrivon Therapeutics, For: Dec 31
Form 4 Acrivon Therapeutics, For: Mar 01 Filed by: Peterson Katharine
Form 4 Acrivon Therapeutics, For: Mar 01 Filed by: Levy Adam D.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.